Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease ResearchClinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature.Castleman Disease Pathogenesis.The full spectrum of Castleman disease: 273 patients studied over 20 years.Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome.The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research.International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseA novel mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman diseaseEffectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman diseaseNovel insights and therapeutic approaches in idiopathic multicentric Castleman diseasePlasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman diseasePredictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataPhase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman diseaseIdentifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseVirome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseaseTreatments administered to the first 9,152 reported cases of COVID19: a systematic reviewTreatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
P50
Q26775808-1007AA20-4B1A-4732-B0D3-6B2FD4C28150Q33429461-8DCA241B-E9EC-4282-991C-B7EB4C62BE5AQ33438403-2628E7D6-BAD4-4E40-BEBE-6528D76DD5D9Q33438812-130B0253-E421-4B87-A3B8-34CA89B68C91Q40366614-B80D2563-EE7A-49CF-96B8-DD345CE5D57CQ42364525-C1B80CFB-993C-4F7A-AF2F-6FFA4A433E43Q47382592-8B0DCA28-F954-4A4B-A3EE-DAFB8E3FBE76Q47578601-BD5FFF3D-25BE-4857-8D05-C3BBB7E6C471Q48221132-758DA76F-E677-4967-914A-7BCA1478C8C4Q52983729-B7341818-8899-4FA3-BF88-9B6FE911ED9FQ57161074-7C6A562C-7367-470D-A3CE-0AF7274F9235Q58554162-E17B2EEA-DBF4-4FD8-B5AC-37E75E7C3C4AQ59348964-03626F9A-AD82-429F-8B92-2CA2D4D0DAB0Q59349702-D89FE8F7-281C-4EA8-8771-BB4792466F88Q88418129-71E55211-C55F-4E9A-8DF6-5F6CAF7B1A7DQ91379532-B7A2AC68-1DBA-4C0A-B317-83B4473860A9Q91555943-CD667645-F5AE-4366-A6F6-E9E7D1E4EBCEQ92592902-82D55CC7-EBC6-4764-B1C3-D15CCFC0D3A1Q93046253-0B67127A-CC3B-4979-8CC2-ECBA169042C3Q95627629-76740824-F55C-4C00-9F94-320F8904CA49Q95937412-B1B44F2E-E34F-461C-8155-F7EE8791A78D
P50
description
American immunologist
@en
onderzoeker
@nl
հետազոտող
@hy
name
David C Fajgenbaum
@ast
David C Fajgenbaum
@es
David C Fajgenbaum
@nl
David C Fajgenbaum
@sl
David Fajgenbaum
@en
type
label
David C Fajgenbaum
@ast
David C Fajgenbaum
@es
David C Fajgenbaum
@nl
David C Fajgenbaum
@sl
David Fajgenbaum
@en
altLabel
D. C. Fajgenbaum
@en
DC Fajgenbaum
@en
David C Fajgenbaum
@en
David C. Fajgenbaum
@en
Fajgenbaum
@en
prefLabel
David C Fajgenbaum
@ast
David C Fajgenbaum
@es
David C Fajgenbaum
@nl
David C Fajgenbaum
@sl
David Fajgenbaum
@en
P214
P244
P106
P21
P214
P244
n2015014072
P31
P496
0000-0002-7367-8184
P735
P7859
lccn-n2015014072